Abstract
The use of blood donor history and state-of-the-art FDA-licensed serological and nucleic acid testing (NAT) assays have greatly reduced the “infectious window” for several transfusion-transmitted pathogens. Currently transmission of human immunodeficiency virus (HIV), Human T-cell Lymphotropic Virus (HTLV), hepatitis viruses and West Nile Virus are rare events. The seroprevalence of cytomegalovirus in the donor population is high and cytomegalovirus infection can cause significant complications for immunocompromised recipients of blood transfusion. Careful use of CMV seronegative blood resources and leukoreduction of blood products are able to prevent most CMV infections in these patients. Currently, bacterial contamination of platelet concentrates is the greatest remaining infectious disease risk in blood transfusion. Specialized donor collection procedures reduce the risk of bacterial contamination of blood products; blood culture and surrogate testing procedures are used to detect potential bacterially contaminated platelet products prior to transfusion. A rapid quantitative immunoassay is now available to test for the presence of lipotechoic acid and lipopolysaccharide bacterial products prior to platelet transfusion. Attention has now turned to emerging infectious diseases including variant Creutzfeldt-Jakob disease, dengue, babesiosis, Chagas disease and malaria. Challenges are presented to identify and prevent transmission of these agents. Several methods are being used or in development to reduce infectivity of blood products, including solvent-detergent processing of plasma and nucleic acid cross-linking via photochemical reactions with methylene blue, riboflavin, psoralen and alkylating agents. Several opportunities exist to further improve blood safety through advances in infectious disease screening and pathogen inactivation methods.
Keywords: Transfusion, infection risk, bacterial contamination, sepsis, screening, emerging infectious agents, pathogen inactivation, leukocytes, Blood Banking, Transfusion Practice, human immunodeficiency virus (HIV), Human T-cell Lymphotropic Virus (HTLV), hepatitis viruses, West Nile Virus, cytomegalovirus, blood transfusion, seronegative, platelet concentrates, immunoassay, variant Creutzfeldt-Jakob disease, dengue, babesiosis, Chagas' disease, malaria, plasma, methylene blue, riboflavin, psoralen, alkylating agents, Nucleic acid testing, hepatitis B virus (HBV) surface antigen (HBsAg), Staphylococcus aureus, S. epidermidis, Klebsiella, Serratia, Staphylococcus, Propionibacterium, Pseudomonas spp, Enterobacter spp, Campylobacter spp, Escherichia coli, Yersinia enterocolitica, Bacillus cereus, Bacterial Sepsis, Spirochetes, Rickettsias
Infectious Disorders - Drug Targets
Title: Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice
Volume: 11 Issue: 1
Author(s): Paul F. Lindholm, Kyle Annen and Glenn Ramsey
Affiliation:
Keywords: Transfusion, infection risk, bacterial contamination, sepsis, screening, emerging infectious agents, pathogen inactivation, leukocytes, Blood Banking, Transfusion Practice, human immunodeficiency virus (HIV), Human T-cell Lymphotropic Virus (HTLV), hepatitis viruses, West Nile Virus, cytomegalovirus, blood transfusion, seronegative, platelet concentrates, immunoassay, variant Creutzfeldt-Jakob disease, dengue, babesiosis, Chagas' disease, malaria, plasma, methylene blue, riboflavin, psoralen, alkylating agents, Nucleic acid testing, hepatitis B virus (HBV) surface antigen (HBsAg), Staphylococcus aureus, S. epidermidis, Klebsiella, Serratia, Staphylococcus, Propionibacterium, Pseudomonas spp, Enterobacter spp, Campylobacter spp, Escherichia coli, Yersinia enterocolitica, Bacillus cereus, Bacterial Sepsis, Spirochetes, Rickettsias
Abstract: The use of blood donor history and state-of-the-art FDA-licensed serological and nucleic acid testing (NAT) assays have greatly reduced the “infectious window” for several transfusion-transmitted pathogens. Currently transmission of human immunodeficiency virus (HIV), Human T-cell Lymphotropic Virus (HTLV), hepatitis viruses and West Nile Virus are rare events. The seroprevalence of cytomegalovirus in the donor population is high and cytomegalovirus infection can cause significant complications for immunocompromised recipients of blood transfusion. Careful use of CMV seronegative blood resources and leukoreduction of blood products are able to prevent most CMV infections in these patients. Currently, bacterial contamination of platelet concentrates is the greatest remaining infectious disease risk in blood transfusion. Specialized donor collection procedures reduce the risk of bacterial contamination of blood products; blood culture and surrogate testing procedures are used to detect potential bacterially contaminated platelet products prior to transfusion. A rapid quantitative immunoassay is now available to test for the presence of lipotechoic acid and lipopolysaccharide bacterial products prior to platelet transfusion. Attention has now turned to emerging infectious diseases including variant Creutzfeldt-Jakob disease, dengue, babesiosis, Chagas disease and malaria. Challenges are presented to identify and prevent transmission of these agents. Several methods are being used or in development to reduce infectivity of blood products, including solvent-detergent processing of plasma and nucleic acid cross-linking via photochemical reactions with methylene blue, riboflavin, psoralen and alkylating agents. Several opportunities exist to further improve blood safety through advances in infectious disease screening and pathogen inactivation methods.
Export Options
About this article
Cite this article as:
F. Lindholm Paul, Annen Kyle and Ramsey Glenn, Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice, Infectious Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152611794407746
DOI https://dx.doi.org/10.2174/187152611794407746 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders
Current Drug Metabolism Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies
Current Cancer Therapy Reviews Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Pathophysiology of Myocardial Infarction and Acute Management Strategies
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiopulmonary Interactions in Children with Heart Failure
Current Cardiology Reviews The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Tenofovir-Related Nephropathies in HIV-Infected Patients
Current Vascular Pharmacology Physiological Significance and Therapeutic Potential of Adrenomedullin in Pulmonary Hypertension
Cardiovascular & Hematological Disorders-Drug Targets Revision on Renal Sympathetic Ablation in the Treatment of Resistant Hypertension
Current Hypertension Reviews Editorial: Pharmacological Therapy to Prevent Sudden Cardiac Death: Indications and Limitations in the Era of Devices
Mini-Reviews in Medicinal Chemistry Improvement of Nerve Fiber Density in Fibromyalgia Patients Treated with IVIg
Current Rheumatology Reviews Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Current Pharmaceutical Design Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Age-Related Changes and Effects of Mild Hypothermia on Carotid Artery Reactivity in Newborn Rats
CNS & Neurological Disorders - Drug Targets